BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013;54:84-8. [PMID: 23220071 DOI: 10.1016/j.molimm.2012.10.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Michels MAHM, Volokhina EB, van de Kar NCAJ, van den Heuvel LPWJ. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy? Pediatr Nephrol 2019;34:1349-67. [PMID: 30141176 DOI: 10.1007/s00467-018-4042-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
2 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
3 Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-8. [DOI: 10.1111/jth.12615] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
4 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
5 Pauly D, Nagel BM, Reinders J, Killian T, Wulf M, Ackermann S, Ehrenstein B, Zipfel PF, Skerka C, Weber BH. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One. 2014;9:e96371. [PMID: 24797388 DOI: 10.1371/journal.pone.0096371] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
6 Lintner KE, Wu YL, Yang Y, Spencer CH, Hauptmann G, Hebert LA, Atkinson JP, Yu CY. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol 2016;7:36. [PMID: 26913032 DOI: 10.3389/fimmu.2016.00036] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 14.0] [Reference Citation Analysis]
7 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
8 Riedl M, Noone DG, Khan MA, Pluthero FG, Kahr WHA, Palaniyar N, Licht C. Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney Int Rep 2017;2:66-75. [PMID: 29142942 DOI: 10.1016/j.ekir.2016.08.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
9 Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol 2013;56:191-8. [PMID: 23816404 DOI: 10.1016/j.molimm.2013.06.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
10 Yun JW, Oh J, Lee KO, Lee SJ, Kim JO, Kim NK, Kim JS, Koh Y, Yoon SS, Yhim HY, Jo SK, Park Y, Lee JE, Park J, Lee JW, Kim SH, Kim HJ, Oh D; Korean TTP Registry investigators., aHUS working group. Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. Thromb Res 2020;194:45-53. [PMID: 33213850 DOI: 10.1016/j.thromres.2020.06.016] [Reference Citation Analysis]
11 Yuen J, Pluthero FG, Douda DN, Riedl M, Cherry A, Ulanova M, Kahr WH, Palaniyar N, Licht C. NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol 2016;7:137. [PMID: 27148258 DOI: 10.3389/fimmu.2016.00137] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
12 Saggu G, Cortes C, Emch HN, Ramirez G, Worth RG, Ferreira VP. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013;190:6457-67. [PMID: 23677468 DOI: 10.4049/jimmunol.1300610] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
13 Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181:306-13. [PMID: 25079699 DOI: 10.1111/cei.12426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
14 Quiroga B, de Lorenzo A, Vega C, de Alvaro F. A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome. Am J Case Rep 2016;17:950-6. [PMID: 27974740 DOI: 10.12659/ajcr.899764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Atkinson JP, Yu CY. The Complement System in Systemic Lupus Erythematosus. Systemic Lupus Erythematosus. Elsevier; 2016. pp. 81-112. [DOI: 10.1016/b978-0-12-801917-7.00012-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Riedl Khursigara M, Schlam D, Noone DG, Bruno V, Ortiz-Sandoval CG, Pluthero FG, Kahr WHA, Bowman ML, James P, Grinstein S, Licht C. Vascular endothelial cells evade complement-mediated membrane injury via Weibel-Palade body mobilization. J Thromb Haemost 2020;18:1484-94. [PMID: 32073731 DOI: 10.1111/jth.14767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
18 Vignesh P, Rawat A, Sharma M, Singh S. Complement in autoimmune diseases. Clinica Chimica Acta 2017;465:123-30. [DOI: 10.1016/j.cca.2016.12.017] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 10.6] [Reference Citation Analysis]
19 Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 2014;8:307. [PMID: 25219386 DOI: 10.1186/1752-1947-8-307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]